|Articles|July 7, 2016

Air Pollution Linked With Increased Risk of Various Cancers

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a study that looked at the link between air pollution and the risk of various cancers.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a study that looked at the link between air pollution and the risk of various cancers.

The study, published in Cancer Epidemiology, Biomarkers & Prevention, followed 66,820 people in Hong Kong from 1998 until 2011, and calculated the annual concentrations of particulate matter at their residential addresses, examining the link between particulate matter and cause of death.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr Microbe - stock.adobe.com

October 24th, 2026

Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer

Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.

The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.

October 24th, 2026

Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC

The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.

October 24th, 2026

INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma

Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

October 24th, 2026

Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.

October 24th, 2026

Narrowing Breast Cancer Disparities Through Collaborative Research and Trial Representation

“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.

October 24th, 2026

Emactuzumab Yields Improved Response Rates in Tenosynovial Giant Cell Tumor

In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.